J. M. Waples

Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).

Chandra P. Belani, David Waterhouse, Hassan Ghazal et al. · Journal of Clinical Oncology · 2010 · 98 citations

Advanced Nsclc, Oncology, Cancer Management +10

Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant

Marc Zumberg, J. M. Waples, Kuo-Jang Kao et al. · American Journal of Hematology · 2000 · 27 citations · Full text

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer

J. M. Waples, Michael Auerbach, Ralph V. Boccia et al. · Journal of Clinical Oncology · 2007 · 22 citations

Acceptable Safety Profile, Phase Ii, Medicine +15

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

J. Stephenson, Marshall T. Schreeder, J. M. Waples et al. · Journal of Clinical Oncology · 2007 · 17 citations

Pharmacotherapy, Tumor Biology, Oncology +20

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)

J. M. Waples, Michael Auerbach, Ronald G. Steis et al. · Journal of Clinical Oncology · 2008 · 13 citations

Oncology, Cancer Therapeutics, Median Survival +14